Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC
The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.
Related Articles
Cell-Free DNA Assay Achieves High Negative Predicative Value in Lung Cancer
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
10 years in, HICOR’s efforts boost cancer care’s value
Fred Hutch public health researchers Drs. Scott Ramsey and Veena Shankaran welcomed stakeholders to the 2024 Value in Cancer Care Summit held November 15, thanking…
Predictive ability of the Cancer and Aging Research Group chemotherapy toxicity calculator in hematologic malignancy
Chemotherapy toxicity tools are rarely studied in patients with hematologic malignancy (HM). The primary aim of this pilot study was to determine the predictive ability…
212Pb-DOTAMTATE Appears Safe, Effective in PRRT-Naïve Patients With SSTR+ GEP-NETs
212Pb-DOTAMTATE demonstrated activity and was considered well tolerated in patients with unresectable or metastatic SSTR+ GEP-NETs who had not received prior PRRT.
Management of Stage III Non–Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights | JCO Oncology Practice
This clinical insights article is derived from recommendations in Management of Stage III Non-Small Cell Lung Cancer: ASCO Rapid Guideline Update. This document is based…
The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality
One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and…
Adding Cancer Vaccine to Avelumab Doesn’t Boost PFS in Gynecologic Cancer
The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.
Registration – December 2024 Coding and Coverage Seminar – American Society for Radiation Oncology (ASTRO) – American Society for Radiation Oncology (ASTRO)
Learn more about when and how to register for the December 2024 ASTRO Coding and Coverage Seminar
Introduction to a review series on von Willebrand factor, factor VIII, and factor IX
Edited and introduced by Associate Editor Thomas Ortel, this review series features 3 reviews of von Willebrand factor, factor VIII, and factor IX. These 3
Welcome! You are invited to join a webinar: SSO CGSO Videoconference: Career Discussions in Surgical Oncology. After registering, you will receive a confirmation email about joining the webinar.
Welcome! You are invited to join a webinar: SSO CGSO Videoconference: Career Discussions in Surgical Oncology. After registering, you will receive a confirmation email about…
